Table 1 Baseline characteristics
From: Low serum eicosapentaenoic acid / arachidonic acid ratio in male subjects with visceral obesity
n (Male) | 134 |
Age, years | 64±12 (25–86) |
Body mass index (BMI), kg/m2 | 25.6±3.9 (18.1-38.5) |
Waist circumference (WC), cm | 90.6±10.7 (68–130) |
Estimated visceral fat area (eVFA), cm2 | 142±60 (36–371) |
History of smoking (%) | 82.1 |
Brinkman index | 747±666 (0–3520) |
Hypertension (%) | 66.4 |
(calcium channel antagonist / angiotensin converting enzyme inhibitor or angiotensin receptor blocker / eplerenone / aliskiren fumarate / beta blockade / diuretics / alpha blockade ) | (n=49/60/1/1/13/15/2) |
Systolic blood pressure (SBP), mmHg | 132±16 (94–180) |
Diastolic blood pressure (DBP), mmHg | 76±11 (52–111) |
Diabetes (%) | 78.4 |
(sulfonyl ureas / glinides / biguanides / pioglitazone /alpha glucosidase inhibitors / dipeptidyl peptidase-IV inhibitors / glucagon-like peptide-1 agonists / Insulin) | (n=42/3/25/24/21/11/1/20) |
Fasting blood glucose (FBG), mg/dL | 128±35 (56–261) |
Hemoglobin A1c (HbA1c), (NGSP),% | 6.9±1.1 (4.9-10.7) |
HOMA-IR, units | 3.1±2.4 (0.47-14.1) |
Estimated glomerular filtration rate (eGFR), mL/min | 69.5±17.7 (24.4-110.6) |
Urine albumin-creatinine ratio (UACR), mg/g creatinine | 175.1±552.0 (0.5-3958) |
Dyslipidemia (%) | 67.9 |
(statins / fibrates / ezetimibe / cholestimide / probucol) | (n=59/3/5/1/2) |
Total cholesterol (T-cho), mg/dL | 192±37 (112–335) |
Low-density lipoprotein-cholesterol (LDL-C), mg/dL | 112±33 (55–259) |
Triglyceride (TG), mg/dL | 142±91 (32–681) |
High-density lipoprotein-cholesterol (HDL-C), mg/dL | 53±16 (23–157) |
Metabolic syndrome (%) | 55.2 |
Eicosapentaenoic acid (EPA), μg/mL | 63.8±35.7 (11.1-212.4) |
Docosahexaenoic acid (DHA) , μg/mL | 140.0±67.3 (41–610.3) |
Arachidonic acid (AA), μg/mL | 172.1±53.5 (72.5-413.4) |
EPA/AA ratio | 0.39±0.24 (0.09-1.41) |
DHA/AA ratio | 0.83±0.32 (0.35-1.98) |
(EPA+DHA)/AA ratio | 1.23±0.52 (0.45-3.27) |
History of coronary artery diseases (CAD) (%) | 39.6 |